Last updated: February 4, 2026
Sponsor: Dartmouth-Hitchcock Medical Center
Overall Status: Active - Recruiting
Phase
N/A
Condition
Neurofibromatosis
Brain Cancer
Brain Tumor
Treatment
Conventional histologic evaluation
CONVIVO system
Clinical Study ID
NCT05139277
D20056
NCI-2023-06342
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Adult patients (age>18)
Adults presenting with suspected intracranial gliomas (including glioblastoma),cerebral metastasis, meningiomas, acoustic neuromas, and pituitary adenomas, who aresurgical candidates
Adults able to provide informed consent.
Exclusion
Exclusion Criteria:
Pregnancy
Children (age <18 years)
Fluorescein sodium (FNa) allergy
Study Design
Total Participants: 30
Treatment Group(s): 2
Primary Treatment: Conventional histologic evaluation
Phase:
Study Start date:
June 28, 2022
Estimated Completion Date:
October 31, 2026
Study Description
Connect with a study center
Dartmouth-Hitchcock Medical Center
Lebanon 5088597, New Hampshire 5090174 03756
United StatesActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.